Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Q2 2023 vs. Q1 2023
How the institutions holding Navidea Biopharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 30 | 23 | −7 |
| Shares | 1.40M | 1.51M | +101.6K (+7.2%) |
| Value | $364.4K | $138.5K | −$225.9K (−62.0%) |
New holders (5)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 125,866 | $11.6K | 0.00% |
| Boothbay Fund Management, LLC | 40,000 | $3.68K | 0.00% |
| Cubist Systematic Strategies, LLC | 10,003 | $920 | 0.00% |
| Group One Trading, L.P. | 300 | $28 | 0.00% |
| Northwestern Mutual Wealth Management Co | 110 | $10 | 0.00% |
Sold out (12)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Renaissance Technologies LLC | 238,133 | $62.0K |
| Millennium Management LLC | 128,756 | $33.0K |
| Bridgeway Capital Management, LLC | 102,440 | $26.6K |
| Citadel Advisors LLC | 65,807 | $17.1K |
| Warberg Asset Management LLC | 28,026 | $7.29K |
| Simplex Trading, LLC | 28,416 | $7.00K |
| Wolverine Trading, LLC | 16,297 | $5.00K |
| Virtu Financial LLC | 16,301 | $4.00K |
| FMR LLC | 1,000 | $260 |
| Advisory Services Network, LLC | 250 | $65 |
| Country Trust Bank | 7 | $2 |
| Royal Bank of Canada | 1 | $0 |